Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-2.96 Insider Own0.40% Shs Outstand174.33M Perf Week0.57%
Market Cap14.41B Forward P/E- EPS next Y-1.08 Insider Trans-59.23% Shs Float171.14M Perf Month-9.96%
Income-482.90M PEG- EPS next Q-0.38 Inst Own100.00% Short Float4.50% Perf Quarter-14.09%
Sales1.04B P/S13.80 EPS this Y-17.30% Inst Trans6.86% Short Ratio6.02 Perf Half Y3.21%
Book/sh15.78 P/B5.24 EPS next Y71.50% ROA-13.50% Target Price114.11 Perf Year-14.45%
Cash/sh5.94 P/C13.93 EPS next 5Y25.00% ROE-20.90% 52W Range62.12 - 107.56 Perf YTD-21.08%
Dividend- P/FCF- EPS past 5Y-21.30% ROI-4.20% 52W High-23.13% Beta1.56
Dividend %- Quick Ratio3.50 Sales past 5Y18.80% Gross Margin82.00% 52W Low33.10% ATR3.48
Employees2158 Current Ratio4.40 Sales Q/Q34.00% Oper. Margin-58.60% RSI (14)42.24 Volatility3.77% 3.65%
OptionableYes Debt/Eq0.26 EPS Q/Q54.80% Profit Margin-46.20% Rel Volume1.44 Prev Close83.51
ShortableYes LT Debt/Eq0.25 EarningsOct 27 AMC Payout- Avg Volume1.28M Price82.68
Recom1.80 SMA20-5.26% SMA50-4.74% SMA200-6.13% Volume1,843,281 Change-0.99%
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Sep-01-15Initiated Raymond James Outperform $148
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Dec-09-16 04:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Dec-08-16 03:06PM  [$$] Would Gilead Buy BioMarin? at Barrons.com
09:47AM  Coverage initiated on BioMarin Pharm by Gabelli & Co
Dec-07-16 07:33AM  Do Hedge Funds Love Agilent Technologies Inc (A)? at Insider Monkey
Dec-06-16 10:38AM  Hedge Funds Are Buying BioMarin Pharmaceutical Inc. (BMRN) at Insider Monkey
Dec-04-16 01:04PM  7 of the Most Shocking Biotech Pipeline Blowups of 2016 at Motley Fool
Dec-02-16 04:17PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
Nov-29-16 11:58AM  BioMarin Surging Beneath the Surface
Nov-23-16 07:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $12.1 million of Shares
10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool
Nov-22-16 12:11PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 22, 2016
Nov-21-16 07:20AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : November 21, 2016
Nov-17-16 09:28AM  10 biotech companies ripe for a buyout, courtesy of Donald Trump at MarketWatch
Nov-16-16 08:48AM  Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y
Nov-15-16 04:18PM  Soros 13F Points to More Than Just Emerging Markets at Investopedia
10:21AM  Why BioMarin (BMRN) Could Be Positioned for a Surge
Nov-11-16 07:16AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : November 11, 2016
Nov-09-16 10:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $11.6 million of Shares +10.07%
04:49PM  BioMarin Rises On 'Life-Changing' Hemophilia Drug, Trump Victory
04:33PM  Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'
04:10PM  Why These Biotechs Are Soaring Today at Motley Fool
01:04PM  BIOMARIN PHARMACEUTICAL INC Financials
12:52PM  Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'
Nov-08-16 05:35PM  Palo Alto Investorss Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns at Insider Monkey
03:12PM  BioMarin's Stock Tumbled in October. Is It Now a Buy? at Motley Fool
Nov-07-16 10:19AM  Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself
Nov-03-16 09:05AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
08:30AM  BioMarin to Attend Three Upcoming Investor Conferences GlobeNewswire
Nov-02-16 10:05AM  Strensiq: A Potential Driver for Alexion
08:05AM  An Update on Phase 3 Studies for Soliris
Nov-01-16 11:52AM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 1, 2016
Oct-31-16 11:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million of Shares
06:04PM  Analyst Recommendations for BioMarin after Its 3Q16 Earnings
04:04PM  BioMarins Product-Specific Performance in 3Q16
03:04PM  BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline at Motley Fool
02:12PM  BioMarins Disappointing 3Q16 Earnings
11:38AM  Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y
10:16AM  ImmunoGen (IMGN) Reports Wider-than-Expected Loss
10:11AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016
Oct-28-16 04:21PM  No. 1 Biotech Amgen Dives As Rebates Chip Away At 2017 Sales View
01:55PM  Seattle Genetics (SGEN) Loss Narrower than Expected in Q3
01:43PM  No. 1 Biotech Amgen Dives As Rebates Chip Away At 2017 Sales View
11:23AM  AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates
10:21AM  BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus
09:35AM  Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
08:25AM  Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y
08:24AM  McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View
Oct-27-16 05:06PM  BioMarin reports 3Q loss
04:17PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:03PM  BioMarin Announces Third Quarter 2016 Financial Results GlobeNewswire
03:44PM  Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View
11:45AM  Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook
11:42AM  Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View
11:22AM  Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View
10:33AM  The Medicines Co. (MDCO) Q3 Loss Narrower than Expected
08:45AM  ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%
07:07AM  Q3 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
Oct-26-16 02:50PM  10 Most Successful Innovative Companies in The World in 2016 at Insider Monkey
09:17AM  Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag
Oct-25-16 04:32PM  Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
10:04AM  Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View
Oct-24-16 09:35AM  Merck Gets FDA Approval for Investigational Drug Zinplava
Oct-23-16 10:35AM  Top Health Care Earnings Coming Next Week at 24/7 Wall St.
Oct-21-16 09:25AM  Alkermes Depression Candidate Positive in Phase III Study
Oct-20-16 04:48PM  BioMarin Could Reap $1.1 Billion In 2025 On 'Dwarfism' Drug: Analyst
11:46AM  A Look At The Science Behind BioMarin Pharmaceutical Inc. (BMRN)s Next Pivotal Candidate at Insider Monkey
09:56AM  What's in Store for BioMarin (BMRN) This Earnings Season?
07:51AM  Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma
Oct-19-16 06:04PM  Will Alexion Beat Investor Expectations in Its 3Q16 Earnings?
05:01PM  BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting GlobeNewswire
03:55PM  How Much Return Could Alexion Offer over the Next 12 months?
09:56AM  AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted
08:30AM  The Medicines Co. Reports Positive Phase II Data on PCSK9si
08:23AM  3 Top Stocks for Your Roth IRA at Motley Fool
Oct-18-16 01:04PM  Vertex Not the Only Pharmaceutical to See Its Share Price Fall
10:05AM  J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
09:23AM  Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia
Oct-17-16 11:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $5.6 million of Shares
08:57AM  Allergan's Belkyra Gets Swedish Approval for Double Chin
08:44AM  Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion
08:32AM  PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
Oct-14-16 10:23AM  BioMarin Issues Encouraging Update on Hemophilia A Drug
10:03AM  Sunesis Submits Response to Questions on Leukemia Drug
09:59AM  OncoGenex Cancer Drug Fails in Phase III Study, Stock Down
Oct-13-16 04:01PM  UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A GlobeNewswire
02:25PM  Supernus (SUPN) Reports Encouraging Data from ADHD Study
11:39AM  Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
10:16AM  What Makes Vertex Pharmaceuticals (VRTX) a Strong Sell?
09:59AM  AMAG Issues Encouraging Updates on Makena & Feraheme
Oct-12-16 07:28AM  3 Biotechs Most Likely to Be Acquired at Motley Fool
Oct-11-16 08:30AM  BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET GlobeNewswire
Oct-10-16 05:42PM  3 biotech breakouts
Oct-06-16 08:52AM  New Strong Buy Stocks for October 6th Zacks
Oct-04-16 11:34AM  Why Sarepta's Licensing Deal Makes This Drug Maker An "Even More Attractive M&A Candidate" at Barrons.com
Oct-02-16 09:57AM  Is Sarepta Therapeutics Still a Risky Bet? at Motley Fool
Sep-30-16 10:05AM  What Do Analysts Say about Regenerons Upside Potential?
08:30AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 30, 2016
Sep-28-16 04:21PM  Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A
12:21PM  Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc at Motley Fool
10:04AM  Whats the Upward Return Potential for BioMarin?
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Kyndrisa, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 044, BMN 045, and BMN 053 for DMD treatment; cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis; and BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate for the treatment of hemophilia A. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as alpha-N-acetyglucosaminidase. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FUCHS HENRY JPresident, Worldwide R&DNov 25Option Exercise26.4915,000397,350128,878Nov 29 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Sale87.4015,0001,310,988113,878Nov 29 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise26.4969,7431,847,492240,425Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale85.6969,7435,976,515170,682Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Option Exercise26.4969,7441,847,519240,426Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Sale87.5669,7446,106,478170,682Nov 23 04:42 PM
Davis George EricEVP, General CounselNov 18Option Exercise38.595,000192,95075,798Nov 22 07:13 PM
Davis George EricEVP, General CounselNov 18Sale90.425,000452,10070,798Nov 22 07:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Option Exercise17.5441,670730,892365,038Nov 18 05:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Sale90.9741,6703,790,795323,368Nov 18 05:37 PM
LAWLIS V BRYANDirectorNov 09Option Exercise17.337,500129,97521,360Nov 14 01:59 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 09Sale90.6120,0001,812,20623,100Nov 14 02:02 PM
LAWLIS V BRYANDirectorNov 09Sale95.007,500712,50013,860Nov 14 01:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Sale82.8370,0005,797,806323,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Sale82.5270,0005,776,435323,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 28Option Exercise14.3960,000863,400383,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 28Sale81.2760,0004,875,990323,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 27Option Exercise14.3960,000863,400383,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 27Sale81.3460,0004,880,448323,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 17Option Exercise17.5441,666730,822365,034Oct 19 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 17Sale84.3941,6663,516,227323,368Oct 19 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 14Option Exercise17.8611,000196,460334,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 14Sale86.8911,000955,814323,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 13Option Exercise38.5953,1252,050,094376,493Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 13Sale86.9853,1254,620,563323,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 30Option Exercise38.5953,1252,050,094431,709Oct 04 03:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 30Sale92.0253,1254,888,780378,584Oct 04 03:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 29Option Exercise38.5953,1252,050,094431,709Oct 03 06:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 29Sale93.6553,1254,974,901378,584Oct 03 06:37 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 27Sale95.6118,4671,765,64841,342Sep 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Option Exercise29.3494,7912,780,915431,709Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Sale95.5694,7919,058,600378,584Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Option Exercise17.3342,577737,859421,161Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Sale94.8542,5774,038,360378,584Sep 19 06:41 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Option Exercise26.4915,000397,350128,878Aug 30 09:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Sale95.0615,0001,425,924113,878Aug 30 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Option Exercise17.5441,666730,822420,250Aug 17 04:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Sale91.4941,6663,811,868378,584Aug 17 04:37 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale99.334,000397,32042,944Aug 03 10:19 AM
Davis George EricEVP, General CounselAug 01Sale100.002,167216,70071,158Aug 03 10:13 AM
Mueller BrianVP, Corporate ControllerAug 01Sale100.0028728,70014,260Aug 03 10:12 AM
LAWLIS V BRYANDirectorJul 27Option Exercise17.331,10019,06314,960Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 27Sale95.391,100104,92713,860Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 22Option Exercise17.336,400110,91220,260Jul 26 06:57 PM
LAWLIS V BRYANDirectorJul 22Sale95.016,400608,06413,860Jul 26 06:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Option Exercise17.5441,666730,822420,250Jul 20 07:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Sale92.7241,6663,863,272378,584Jul 20 07:51 PM
Davis George EricEVP, General CounselJul 14Option Exercise38.592,656102,49573,325Jul 18 06:02 PM
Davis George EricEVP, General CounselJul 07Sale90.002,167195,03070,669Jul 11 04:45 PM
LAWLIS V BRYANDirectorJun 20Sale82.7755045,52413,860Jun 21 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Option Exercise17.5441,666730,822420,250Jun 20 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Sale80.5541,6663,356,196378,584Jun 20 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 06Sale89.141,649146,99246,944Jun 08 08:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Option Exercise39.0616,896659,95871,235Jun 02 06:21 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Sale89.8820,8411,873,12650,394Jun 02 06:21 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Option Exercise26.4915,000397,350130,914May 31 06:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Sale87.8115,0001,317,100115,914May 31 06:52 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 23Sale87.073,769328,18458,644May 25 02:57 PM
BAFFI ROBERTEVP, Technical OperationsMay 18Sale87.055,000435,249130,386May 19 03:53 PM
Davis George EricEVP, General CounselMay 10Sale86.324,658402,07975,540May 10 07:06 PM
Davis George EricEVP, General CounselMay 09Sale84.5510,000845,53280,198May 10 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise12.9960,000779,40020,000May 09 08:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale80.1550,0004,007,4450May 09 08:47 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 03Sale86.0341535,70163,072May 04 04:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Option Exercise12.9936,500474,135432,135May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Sale85.0136,5003,102,931395,635May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerApr 06Option Exercise14.391,50021,585395,221Apr 07 08:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,50021,585393,721Apr 07 08:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfficerMar 04Sale88.421,255110,97046,882Mar 07 08:45 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale86.124,623398,12049,688Mar 02 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 01Sale84.2810,000842,769340,500Mar 02 08:38 PM
GREY MICHAEL GDirectorFeb 22Option Exercise38.597,500289,42533,750Feb 23 04:41 PM
GREY MICHAEL GDirectorFeb 22Sale80.007,500600,00026,250Feb 23 04:41 PM